William J Peppard, Anne Daniels, Lynne Fehrenbacher, Jamie Winner

). Read article or submit your manuscript for publishing."/>
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

Review

(3867) Views  (1108) Full article downloads

Authors:

William J Peppard, Anne Daniels, Lynne Fehrenbacher, Jamie Winner

Published Date June 2009 Volume 2009:2 Pages 27 - 40
DOI: http://dx.doi.org/10.2147/IDR.S3794

William J Peppard1, Anne Daniels1, Lynne Fehrenbacher2, Jamie Winner3

1Froedtert Hospital Milwaukee, Wisconsin, USA; 2Aurora St Luke’s Medical Center Milwaukee, Wisconsin, USA; 3Clement J Zablocki VA Medical Center, Milwaukee, Wisconsin, USA

Abstract: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have increased dramatically over the last two decades. The types of infections can range from complicated skin and skin structure infections (cSSSI) to pneumonia and endocarditis. Oral antimicrobial therapy, such as trimethoprim-sulfamethoxazole, clindamycin, long-acting tetracyclines, or linezolid may provide enhanced benefit to those with uncomplicated cutaneous lesions when used in conjunction with incision and drainage in an outpatient setting. However, resistance, susceptibilities, patient-specific circumstances, and adverse effects can impact a healthcare professional’s choice of antibiotics. In patients with complicated infections requiring hospitalization or parenteral treatment, vancomycin remains the drug of choice, even though increased resistance and decreased efficacy have crept into clinical practice. Linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline are alternative intravenous agents for the treatment of CA-MRSA. Investigational agents such as dalbavancin, telavancin, oritivancin, iclaprim, ceftobiprole, ceftaroline, and others may expand our therapeutic armamentarium for the treatment of infections caused by CA-MRSA in the future.

Keywords: community-associated methicillin-resistant Staphylococcus aureus, CA-MRSA, complicated skin and skin structure infections, cSSSI, Panton-Valentine leukocidin, PVL, in vitro activity






 

Other articles by Dr William Peppard



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Everolimus-eluting stents: update on current clinical studies
Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University